References:
1. Lopez Pineiro M, Willis E, Yao C, Chon SY. Pyoderma gangrenosum-like
ulceration of the lower extremity secondary to sunitinib therapy: a case
report. SAGE Open Med Case Rep. 2018;6:2050313X18783048.
2. Gravalos C, Cassinelli J, Fernandez-Ranada I, Holgado E. Role of
tyrosine kinase inhibitors in the treatment of advanced colorectal
cancer. Clin Colorectal Cancer. 2007;6(10):691-9.
3. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al.
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral
multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin
Oncol. 2006;24(1):25-35.
4. Billemont B, Meric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.
[Angiogenesis and renal cell carcinoma]. Bull Cancer. 2007;94 Spec
No:S232-40.
5. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl
J Med. 2014;371(7):654-66.
6. Noronha V, Punatar S, Joshi A, Desphande RV, Prabhash K.
Sunitinib-induced thrombotic microangiopathy. Journal of cancer research
and therapeutics. 2016;12(1):6.
7. Bollée G, Patey N, Cazajous G, Robert C, Goujon J-M, Fakhouri F, et
al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by
sunitinib. Nephrology Dialysis Transplantation. 2009;24(2):682-5.
8. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, et
al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by
sunitinib. Nephrology, dialysis, transplantation : official publication
of the European Dialysis and Transplant Association - European Renal
Association. 2009;24(2):682-5.
9. Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib.
Cancer research and treatment: official journal of Korean Cancer
Association. 2008;40(4):211.
10. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced
hypertension, thrombotic microangiopathy and reversible posterior
leukencephalopathy syndrome. Annals of Oncology. 2007;18(10):1745-7.
11. Talebi TN, Stefanovic A, Merchan J, Lian E, Silva O.
Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
American journal of therapeutics. 2012;19(4):e143-e5.
12. Mancini V, Battaglia M, Ditonno P, Palazzo S, Lastilla G, Montironi
R, et al. Current insights in renal cell cancer pathology. Urol Oncol.
2008;26(3):225-38.
13. Pouessel D, Culine S. Targeted therapies in metastatic renal cell
carcinoma: the light at the end of the tunnel. Expert Rev Anticancer
Ther. 2006;6(12):1761-7.
14. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic
and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a
literature review. Cancer Treat Rev. 2008;34(3):193-205.
15. Gordon MS, Cunningham D. Managing patients treated with bevacizumab
combination therapy. Oncology. 2005;69 Suppl 3:25-33.
16. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et
al. Phase III trial of bevacizumab plus interferon alfa versus
interferon alfa monotherapy in patients with metastatic renal cell
carcinoma: final results of CALGB 90206. J Clin Oncol.
2010;28(13):2137-43.
17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian
SL, et al. A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer. N Engl
J Med. 2003;349(5):427-34.
18. Rini BI. Vascular Endothelial Growth Factor–Targeted Therapy in
Renal Cell Carcinoma: Current Status and Future Directions. Clinical
Cancer Research. 2007;13(4):1098.
19. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al.
Food and Drug Administration drug approval summary: Sunitinib malate for
the treatment of gastrointestinal stromal tumour and advanced renal cell
carcinoma. Oncologist. 2007;12(1):107-13.
20. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, et
al. A preeclampsia-like syndrome characterized by reversible
hypertension and proteinuria induced by the multitargeted kinase
inhibitors sunitinib and sorafenib. J Natl Cancer Inst.
2008;100(4):282-4.
21. Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute
interstitial nephritis associated with the tyrosine kinase inhibitor
sunitinib: a class effect? Nephrol Dial Transplant. 2009;24(2):673-5.
22. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch
J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J
Med. 2008;358(11):1129-36.
23. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular
endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int.
2004;65(6):2003-17.
24. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K,
Kabbinavar F, et al. Arterial thromboembolic events in patients with
metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl
Cancer Inst. 2007;99(16):1232-9.
25. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in
a patient receiving anti-VEGF therapy for metastatic renal cell
carcinoma. Nat Clin Pract Nephrol. 2007;3(5):287-93.
26. Hohenstein B, Braun A, Amann KU, Johnson RJ, Hugo CP. A murine model
of site-specific renal microvascular endothelial injury and thrombotic
microangiopathy. Nephrol Dial Transplant. 2008;23(4):1144-56.